Efficacy evaluation of neoadjuvant chemotherapy in patients with HER2-low expression breast cancer: A real-world retrospective studyLingfeng Tang, Shengchun Liu, Yingkun Xu et al.|Frontiers in Oncology|2022Cited by 10
Comprehensive pan-cancer analysis reveals CDC6 as a potential immunomodulatory agent and promising therapeutic target in pancreatic cancerDongyao Pu, Shengchun Liu, Wenjie Zhang et al.|Translational Cancer Research|2024Cited by 3
Prognosis and influencing factors of ER-positive, HER2-low breast cancer patients with residual disease after neoadjuvant chemotherapy: a retrospective studyLingfeng Tang, Shengchun Liu, Linshan Jiang et al.|Scientific Reports|2024Cited by 2
Abstract PO3-25-12: Tigecycline-Induced Metabolic Reprogramming and Cytokine Modulation Suppress the Characteristics of Breast Cancer CellsHaochen Yu, Shengchun Liu, Lingfeng Tang|Cancer Research|2024Cited by 1
Prognosis and Influencing Factors of ER-positive, HER2-low Patients with Residual Diseases after Neoadjuvant Chemotherapy: A Retrospective StudyLingfeng Tang, Shengchun Liu, Xiujie Shu et al.|Research Square|2023Cited by 0